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Abstract
The 1st International Workshop on Xenotropic Murine Leukemia Virus-Related Retrovirus (XMRV), co-sponsored by
the National Institutes of Health, The Department of Health and Human Services and Abbott Diagnostics, was
convened on September 7/8, 2010 on the NIH campus, Bethesda, MD. Attracting an international audience of over
200 participants, the 2-day event combined a series of plenary talks with updates on different aspects of XMRV
research, addressing basic gammaretrovirus biology, host response, association of XMRV with chronic fatigue
syndrome and prostate cancer, assay development and epidemiology. The current status of XMRV research,
concerns among the scientific community and suggestions for future actions are summarized in this meeting
report.
Introduction
In 2006, Urisman et al. [1] described the identification
and characterization of a novel gammaretrovirus, xeno-
tropic murine leukemia virus-related virus (XMRV), in a
small number of prostate cancers. Subsequent studies of
Schlaberg et al. [2] suggested that XMRV might have a
broader distribution, and was present in both prostate
cancer patients and benign controls. XMRV is very clo-
sely related to endogenous proviruses found in inbred
(laboratory) mice, some of which cause lymphoma and
other diseases in mice. Due to the lack of functional
receptor Xpr1, this virus does not replicate in most
inbred mice, but grows well in human prostate cancer
cell lines. Interest in XMRV has recently intensified fol-
lowing the work of Lombardi et al. [3], who detected
XMRV in chronic fatigue syndrome (CFS) patients in
clusters of cases in Nevada and Florida-South Carolina.
Virus could be detected through both antibodies in
serum and proviral DNA in peripheral blood mononuc-
lear cells (PBMCs), and could easily be cultured from
PBMCs and plasma. However, although these and
related studies demonstrated an association of XMRV
infection with at least two human diseases, causality was
not established.
Despite the significant increase in XMRV-related pub-
lications over the last 24 months, the research commu-
nity has failed to reach consensus on the origin of this
virus, its causative (or passenger) role in disease pathol-
ogy, and the extent to which it is prevalent in the
human population. On the contrary, the numbers of
studies identifying XMRV in humans [1-6] are presently
outweighed by reports from laboratories throughout the
world that have failed to detect the virus [7-15] which
have now added to an increasing sense of confusion.
Central to this has been the lack of standardized nucleic
acid-based or serological methods for detecting viral
nucleic acid and antibodies, respectively, as well as “gold
standard” reference samples with which individual
groups can judge the selectivity and sensitivity of their
protocols. The 1st International Workshop on XMRV
was therefore convened at the National Institutes of
Health, Bethesda, MD on September 7/8, 2010, with a
goal of providing a public forum to discuss these and
related issues, including increasing concerns regarding
mouse DNA contamination, methods of sample hand-
ling and storage, use of antiretrovirals currently available
for HIV therapy, and progress in developing standard
PCR and serological reagents. In his introductory
remarks, NIH Director Dr. Francis Collins urged the
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225 attendees to maintain a healthy skepticism on
potential causative roles of XMRV, indicating that a
solution to this conundrum requires an interdisciplinary
and synergistic effort from researchers in both the pros-
tate cancer and CFS arenas. This report summarizes
overviews and research findings presented during the
2-day International Workshop.
Gammaretrovirus Biology
J. Coffin (Tufts University School of Medicine, Boston,
Massachusetts) opened the Workshop by providing
background information on XMRV and the endogenous
viruses of mice, summarizing the basic properties of
endogenous retroviruses and the original studies with
XMRV before proceeding to examine in more detail
proviruses in the genomes of mice and their effects on
their hosts. Experiments in his laboratory have charac-
terized xenotropic, polytropic and modified polytropic
endogenous proviruses, their distribution across the
mouse genome, co-evolution with different species of
mice, and relationship to viruses associated with pros-
tate cancer and chronic fatigue syndrome. Dr. Coffin’s
concluding statements set the tone for subsequent dis-
cussions of the Workshop. Uppermost in his concerns
were (i), conflicting reports on association with diseases
(ii), lack of insight into potential pathogenic mechanisms
(iii), assay sensitivity used for detecting XMRV and
related viruses (iv), the well documented infection of
human cells passaged through nude mice by xenotropic
MLV possibly initiating further spread, and (v) ubiqui-
tous presence of mice and mouse products likely con-
taining multiple MLV sequences. The magnitude of the
problem was illustrated by considering a swimming pool
into which a drop of mouse blood was introduced, after
which every milliliter of water would contain enough
DNA to give a positive signal using the current ultrasen-
sitive PCR techniques.
S. Chow (University of California, Los Angeles,
California) described studies of the incidence of XMRV
and related MLV in healthy donors and patients with
prostate cancer in two cohorts, one in the U.S. (UCLA)
and the other in China (Second Affiliated Hospital,
Hangzhou, Zhejiang and Ningbo Blood Center, Ningbo,
Zhejiang) using an RT-PCR approach with three differ-
ent primer sets. Individuals were considered positive if
one out of the three tests yielded consistent positives.
Perhaps surprisingly, an equal frequency of positives was
seen in the patient and control groups, and there was a
higher incidence of XMRV or MLV-related virus
sequences associated with increasing age. An association
with the RNase L R462Q mutation previously linked
with prostate cancer was not confirmed. Env primers
yielded the most positive results; including examples of
XMRV, xenotropic, polytropic and modified polytropic
sequences. No examples of the 24-nt deletion in the gag
leader region characteristic of XMRV were detected
with fragments amplified using gag primers. Dr Chow
subsequently described experiments to identify XMRV-
host cell junctions in samples from CFS patients. Such
junction fragments were only found in two XMRV-
positive, patient-derived cell lines [16,17]. The sample
size of XMRV integration sites in tumors is currently
insufficient to detect common integration sites with
which to assess the role of insertional mutagenesis as an
oncogenic mechanism during XMRV infection.
A. Wlodawer (National Cancer Institute (NCI),
Frederick, Maryland) opened his presentation by point-
ing out the contribution of drugs targeting HIV-1 pro-
tease to highly-active antiretroviral therapy, and the
crucial role of structure-based drug design in their
development. Dr. Wlodawer reported the 2Å crystal
structure of XMRV protease, which is responsible for
processing protein polyprotein precursors during virus
maturation. As with related retroviral proteases, the
XMRV protein forms a homodimer, but despite overall
similarities, the XMRV and HIV-1 proteins are quite dif-
ferent, particularly at the dimer interface. Overall, the
structure resembles an internal domain from a human
ubiquitin receptor protein (Ddi1) that may function pro-
teolytically during regulated protein turnover in the cell.
Recombinant XMRV protease showed a tendency for
self-digestion, an observation that will presumably be
used in the development of XMRV protease inhibitors.
An account of this study will appear in Nature Struc-
tural and Molecular Biology.
O. Cingoz (Tufts University, Boston, Massachusetts)
described different approaches to identify a possible
source of XMRV in mice. Sequence comparisons were
conducted to design a pair of PCR primers, spanning (i),
a unique 2-nt insertion in the viral LTR and (ii) the 24-
nt deletion of the gag leader, allowing detection of
XMRV against a background of closely related MLVs.
Screening over 70 inbred laboratory and wild derived
mice failed to identify an endogenous provirus with the
predicted fragment. However in silico analyses showed
that one or more proviruses carrying the 24-nt deletion
is present in several mouse strains, an observation that
was confirmed by single genome PCR amplification and
Southern blotting experiments using an oligonucleotide
probe spanning the deletion. This probe reacts with a
single provirus in these strains whose similarity with
XMRV remains to be determined. Together these obser-
vations strengthen the argument for a murine origin of
XMRV with recombination or mutation providing the
LTR specific change. Dr. Cingoz concluded by describ-
ing a highly sensitive assay for detecting mouse DNA
contamination using primers directed against Intracis-
ternal A-type particle (IAP) sequences, which are
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present at an estimated 1000 copies per haploid genome
[18]. An assay with such sensitivity, possibly comple-
menting one directed against mouse mitochondrial
DNA, would guard against contaminating DNA in
future PCR studies designed to detect XMRV and
related viruses in human samples.
The concluding presentation of R. Molinaro (Emory
University, Atlanta, Georgia) described a novel gene pro-
duct encoded by XMRV, translated from a doubly
spliced env mRNA of 1.2 kb and comprising an 11kD
portion of the C-terminal region of the Envelope poly-
protein. Expression studies with a GFP fusion protein
revealed a punctate pattern of fluorescence present in
both nucleus and cytoplasm. These studies are consis-
tent with, but do not prove, a possible role for the novel
protein in the export of unspliced viral RNA from the
nucleus of XMRV-infected cells.
Host Response
The Host Response session was opened by R. Silverman
(Cleveland Clinic, Cleveland, Ohio), who discussed the
linkage of hereditary prostate cancer with mutations in
the ribonuclease L (RNase L) gene and discovery of
XMRV [1]. In 86 patients, the finding that 8/20 were
homozygous for the QQ mutation in RNase L suggested
a strong correlation [1], confirmed in one study [4] but
not in others [2,5]. Data were presented showing that
RNase L inhibited XMRV replication in cell culture.
Electron microscopy identified an enveloped retrovirus
similar to MLV. A rhesus macaque study with Francois
Villinger and collaborators at Abbott Diagnostics (to be
described), showed that XMRV trafficked to prostate
epithelium within 6-7 days post-infection, but was
observed only in stromal cells after 291 days. Similarly,
in human prostate cancer tissues XMRV was observed
only in a small number of stromal cells [1]. The XMRV
DNA in macaque PBMC in vivo was mutated by APO-
BEC3, relating to the subsequent talk by K. Bishop. The
androgen receptor element in the XMRV LTR U3
region was shown to be sensitive to dihydroxytestoster-
one (DHT) in vitro, and DHT stimulated virus replica-
tion in vitro [19]. Dr. Silverman concluded with a
statement that a causal link of XMRV to any human
disease remains to be established.
In view of the increasing interest in cellular inhibitors
of retroviral replication, K. Bishop (National Institute
for Medical Research, UK) provided an overview of
restriction factors and their impact on XMRV replica-
tion [20]. Human APOBEC3G, a cytidine deaminase,
which potently inhibits HIV replication through lethal
G -> A hypermutation, and to a lesser extent the related
APOBEC3F, were also shown to inhibit XMRV replica-
tion. However, while the HIV accessory protein Vif
counters APOBEC-mediated deamination by targeting it
for proteasomal degradation, XMRV lacks the counter-
part. How XMRV achieves such “resistance” is presently
unclear. Tetherin (CD317/Bst2), a Type II membrane
protein that localizes to multiple membrane compart-
ments, crosslinks nascent virions to the plasma mem-
brane, preventing release of a variety of retroviruses,
filoviruses, gammaherpesviruses and arenaviruses.
XMRV was likewise sensitive to human, simian and
murine tetherins. While HIV-1 Vpu counters tetherin-
mediate XMRV restriction in HeLa cells, the absence of
such an accessory protein in XMRV again begs the
question of how host restriction is bypassed. Also,
XMRV env cannot counteract tetherin. Finally, XMRV
is not sensitive to restriction by the intrinsic immune
factor TRIM5alpha, which can mediate an early block to
HIV-1 replication. However, XMRV is restricted by the
mouse specific restriction factors, Fv1n and Fv1b. Under-
standing how XMRV evades host restriction factors in
the course of natural infection is clearly an important
issue if developing antiviral strategies becomes a priority.
Although the XMRV field is in its infancy, E. Sparger
(University of California at Davis, California) highlighted
issues that must be better understood when considering
vaccine development. These included the mode(s) of
transmission, pathogenesis in the host and immune cor-
relates for control of virus replication. Dr. Sparger’s
comments were based on the success of vaccinating
domestic cats against feline leukemia virus (FeLV), a
related gammaretrovirus identified in 1964. Common
features of FeLV and XMRV include their potential
association with immune suppression, disease of the
central nervous system, and induction of cancer. Suc-
cessful strategies included whole inactivated virus,
recombinant surface glycoprotein, subunit vaccines and
nonadjuvanted canarypox-vectored live vaccine
(ALVAC), with efficacy rates of 44% - 100% reported.
Reiterating the cautious note that pathogenesis and
immune correlates for XMRV must be thoroughly char-
acterized in order to inform vaccine design, Dr. Sparger
concluded by suggesting that newer and more novel
approaches (e.g. vector systems, molecular adjuvants,
inclusion of multiple modalities) should further increase
the likelihood of success.
With the goal of establishing an animal model to
study XMRV dissemination, tissue tropism and
pathogenicity, F. Villinger (Emory University, Atlanta,
Georgia) summarized a collaborative study in which
XMRV-infected rhesus macaques were followed for
various periods of time post-infection and euthanized
during acute infection or during chronic infection 146
and 289 days post-inoculation [21]. Animals were moni-
tored for immune parameters and viral replication as
well as extensive tissue collections and in situ analyses
performed at necropsy. Animals showed transient
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viremia and induction of antibodies as well as infection
of prostate, spleen, liver, lymph nodes, lung and jeju-
num. No evidence of pathogenesis was observed
during the 9-month follow-up, together with antibody
responses that rapidly declined after infection and
mostly undetectable cell mediated immune responses,
suggesting limited antigenic stimulation. However,
detailed in situ analysis of various organs and tissues
detected virus replication at various times post-infection.
Demonstration of XMRV replication in reproductive
organs (prostate, seminal gland, testis as well as vagina
and cervix) suggested a potential for sexual transmis-
sion. In cautioning that expansion of the model is
urgently needed, this study provided a valuable model of
human XMRV infection to assess long-term chronic
infection, pathogenesis, immunity and for validating
potential vaccines.
The use of Gairdner’s Shrewmouse, Mus pahari, as a
small animal model of XMRV infection was presented
by Y. Ikeda (Mayo Clinic, Rochester, Minnesota). The
susceptibility of Mus pahari cells to XMRV is due to
their novel receptor as previously described by C. Kozak
and co-workers [22]. The Kozak laboratory also showed
that no wild mouse is resistant to xenotropic virus and
several laboratory mouse strains are susceptible to
X-MLVs [23,24]. The Ikeda laboratory showed that
M. pahari fibroblasts support XMRV replication
in vitro, while inoculated mice demonstrated high levels
of neutralizing antibodies 2 weeks post-infection. XMRV
proviral DNA was found mainly in blood, spleen and
brain, suggesting the virus was lympho- and neuro-tro-
pic in Mus pahari [25]. Despite some practical difficul-
ties (including small litters, relatively small spleen and a
lack of inbred strains), the Mus pahari model showed
promise.
To uncover additional determinants of virus entry and
identify entry restrictions that could modulate trans-spe-
cies transmissions, C. Kozak (NIAID, Bethesda, Mary-
land) examined evolution of Xpr1 in rodent species and
the co-evolution of Xpr1 and xenotropic/polytropic
MLVs (X/P-MLVs) in Mus species, extending this analy-
sis to non-rodent species. Ten distinct phenotypes were
identified, distinguished by resistance to different X/P-
MLVs, of which four were known Xpr1 variants in Mus
and a novel fifth allele was identified in Mus molossinus
and Mus musculus. The geographic and species distribu-
tion of the five functional Xpr1 variants in Mus and
their evolutionary association with endogenous X/P-
MLVs were described. Specific residues important for
mouse X/P-MLV entry were demonstrated by muta-
tional analysis, which also indicated that, while XMRV
relies on X-MLV entry determinants, it uniquely
requires at least one additional residue. In demonstrat-
ing the highly polymorphic nature of the Xpr1 receptor,
Dr. Kozak emphasized that, although all mammals carry
functional receptors, these differ in their ability to allow
entry of the various human or mouse derived viruses,
reflecting sequence substitutions or deletions in the two
extracellular loops that carry receptor determinants.
XMRV and Prostate Cancer
In his introductory presentation, E. Klein (Cleveland
Clinic, Cleveland, Ohio) addressed four questions: 1)
why is prostate cancer important? 2) is prostate cancer
an infectious disease? 3) what is the role of XMRV in
prostate cancer? 4) what are the implications? Risk fac-
tors for prostate cancer include age, race, family history
and genetic factors that remain largely undefined. Infec-
tions account for several types of cancers, but it is
unknown if infectious agents contribute to prostate can-
cer. However, mutations in genes involved in the host
response to infections or in immunity (e.g., RNASEL,
MSR1 and TLR4) are associated with prostate cancer in
humans. The RNASEL (HPC1) association is seen in
multiple affected family members [26]. RNase L R462Q
has reduced enzyme activity and doubles the risk of
prostate cancer when homozygous [27]. XMRV was dis-
covered in such men (QQ genotype) with prostate can-
cer [1]. Published confirmatory studies of XMRV in
prostate cancer were described [2,4,28], although only
one suggested correlation with the RNASEL QQ geno-
type [4]. Possible reasons for studies failing to detect
such an association [12] are that XMRV may not be
truly associated with human disease, technique differ-
ences (e.g. PCR details and unrecognized sequence var-
iations), and geographical distribution of the virus.
Pathways to viral oncogenesis include insertional muta-
genesis, proinflammatory effects, oncogenic viral pro-
teins, immune suppression and altered epithelial/stromal
interactions. For instance, cancer associated fibroblasts
(but not normal fibroblast) cause initiated epithelial cells
to form large tumors in mice. The implications of
XMRV in prostate cancer include a potential biomarker
for aggressive tumors [2]. In this regard, XMRV RNA
was detected in a subset of expressed prostate secretion
(EPS) specimens from prostate cancer patients. Dr.
Klein closed by suggesting that if XMRV is shown to be
a cause of prostate cancer it could lead to a vaccine,
such as the HPV vaccine used to prevent cervical
cancer.
I. Singh (University of Utah, Salt Lake City, Utah)
reviewed her work on the role of XMRV in prostate
cancer [2] and of antiretroviral drugs on XMRV infec-
tions in cell culture [29]. Compelling reasons for study-
ing XMRV included a large number of prostate cancer
deaths, and a causal role for XMRV could spur new
methods for prevention, biomarkers for disease, help in
resolving difficult cases and antiretroviral therapy.
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Rabbit antisera to XMRV propagated in human 293T
cells was used in immunohistochemistry (IHC) experi-
ments to probe human prostate tumor tissue sections
(23% of which were positive). Infected cells were almost
all of the malignant epithelial type, including clusters of
such cells. In contrast, qPCR showed 6% were XMRV
positive. Differences between the two methods were
attributed to very low viral loads, sampling differences,
and varying proportions of XMRV-infected cells. XMRV
was associated with higher grades of prostate cancer,
but not tumor stage or age at diagnosis. Since associa-
tion between XMRV detection and the RNASEL SNP
for R462Q could not be verified, the entire population
may be susceptible to XMRV infection. Lessons learned
include that very small amounts of virus are present,
contamination from mouse tissues can occur, different
sections of the same tumor may have different amounts
of virus, and that XMRV detection by IHC does not
work well in tissue microarrays.
J. Petros (Emory University, Atlanta, Georgia)
described XMRV variations in prostate cancer cases,
pointing out that there are relatively few SNP variations
between reported XMRV sequences and only limited
full-length XMRV genome sequences in the public
domain. Evidence of XMRV in prostate cancer cases
was obtained by an immunoassay detecting XMRV-neu-
tralizing antibodies, PCR and fluorescence in situ hybri-
dization; results from seven different prostate cancer
patients were in concordance by all three methods [4].
Whole XMRV provirus amplification from malignant
prostate tissues yielded amplicons larger than 9 kb in
contrast to the full-length 8.2 kb genome. The “extra”
DNA has not yet been identified, but smaller provirus
amplicons were also found, indicating both internal
deletions and extensions. Dr. Petros suggested that aber-
rant XMRV integration events and internal deletions
result in substantial variation among integrated XMRV
sequences in prostate cancer tissues.
In contrast, K. Sfanos (Johns Hopkins University, Bal-
timore, Maryland) and co-workers failed to detect
XMRV in prostate cancer and benign tissue, pointing
out no virus has been causally linked to prostate cancer
despite 30 years of searching. A real-time duplex PCR
assay developed in collaboration with A. Rein, NCI, Fre-
derick, Maryland, was described. Both XMRV and CCR5
(a single copy nuclear gene) were amplified in the same
PCR well, the latter confirming the quality of the DNA.
As a positive control, CWR22Rv1 (an XMRV-infected
prostate cancer cell line) genomic DNA was diluted into
HeLa or 293T cell genomic DNA. The assay could
detect ~20 copies of XMRV DNA in a vast excess of
uninfected cell DNA. DNA from 161 prostate tumors
was assayed and, while CCR5 DNA was detected, no
XMRV-specific amplicon was obtained. IHC performed
with polyclonal antisera against MoMLV p30 Capsid
(CA) and gp70 Envelope surface subunit (SU) protein
likewise failed to demonstrate staining of prostate tissues
(596 prostate tumors and 452 benign prostate) with
either antiserum. Possible reasons for the negative
results were that RNASEL R462Q homozygotes were
not selected (a finding that is inconsistent between all of
the studies), that XMRV was not detected because of
sequence variations, or that infected cells are present at
an extremely low level and below the limits of sensitiv-
ity. Differences in PCR and serological methods between
the different studies could also contribute to the differ-
ent findings [7].
N. Fischer (University Medical Center, Hamburg,
Germany) presented on the prevalence of XMRV in
prostate cancer and viral mechanisms in tumorigenesis.
Using RT-PCR of cryo-preserved and fresh prostate tis-
sues, XMRV was found only rarely in sporadic prostate
cancer (1/300) and in 1/70 benign controls [30]. Addi-
tionally, in collaboration with researchers at the Robert
Koch Institute, Berlin, Germany, only 1/50 benign pro-
static hyperplasia cases was positive using polyclonal
antisera, while none of ten high grade prostate cancer
cases was positive. To investigate a possible indirect
mechanism of carcinogenesis involving stromal cell
infections, studies with a cytokine antibody array indi-
cated that several proteins were down-regulated in pros-
tate stromal fibroblasts (PrSc), including TIMP1&2,
IGFBP2&4, HGF, and IL-13. In contrast Gro-a was up-
regulated. Interestingly, XMRV replication enhanced the
migration of LNCaP cells through Matrigel. Dr. Fischer
suggested that XMRV could indirectly contribute to
prostate cancer through infection of stromal cells that
release cytokines affecting cell invasion and tumor
progression.
B. Danielson (Baylor College of Medicine, Houston,
Texas) sought to further define the geographic distribu-
tion of XMRV among prostate cancer patients in the US
by investigating the association with RNASEL R462Q,
and searching for correlations with clinical/pathological
parameters [5]. The study involved 144 prostate cancer
patients from Texas, with no preoperative treatment,
who underwent radical prostatectomy. Of these, 32
(22.2%) were determined to be positive for XMRV.
Nested PCR was used to amplify a 650 bp region of the
env gene, and specimens were considered positive if one
or more of three PCR replicates yielded a correctly-sized
amplicon. PCR products from 17 XMRV positive sam-
ples were sequenced and found to be 98.6-100% identi-
cal to XMRV VP62. XMRV DNA was detected in both
normal and tumor tissues, and a correlation with the
RNASEL QQ genotype could not be established. In addi-
tion, there was no correlation between the presence of
XMRV and tumor grade. Among factors important for
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the detection of XMRV were the level of input DNA
(650 ng) and amplification of the env gene (compared
with gag and pol).
Additional talks summarizing prostate cancer studies
included a presentation of F. Ruscetti (NCI, Frederick,
Maryland). Antibody to XMRV Envelope protein was
detected in plasma from prostate cancer patients and
expressed prostate secretions (EPS). Transmission of
XMRV from prostate cancer plasma and EPS to LNCaP
cells in culture was demonstrated immunologically by
western blotting. Transmission of XMRV from plasma
from NIH prostate cancer patients to LNCaP cells was
also shown by virus culture. Infectious virus and antibo-
dies against XMRV were observed in the blood of some
prostate cancer patients. Finally, virus was detected in
prostate cancer plasma using a novel indicator cell line
developed at the NCI (see description of K. Lee’s pre-
sentation below).
W. Switzer (CDC, Atlanta, Georgia) reported on 162
prostate cancer patients collected at Fox Chase Cancer
Center in Philadelphia, Pennsylvania. Using nested PCR
on prostate tumor tissue DNA, PCR products were
obtained for gag, pol and env from one patient, from pol
and env for a second, and pol alone from a third (all
samples were negative for mouse mitochondrial DNA).
However, PCR was not successful in all replicates on
individual samples (the range of XMRV-positive to total
numbers of replicates was between 1/4 to 7/9). There
was 4.8 to 6.5% divergence in a 167 bp pol sequence
between the newly detected viruses and XMRV strains
in the public databases, and less than 2% divergence in
a 323 bp gag sequence. All 162 plasma samples were
antibody negative using western blot testing. He also
presented negative data on CFS and matched health
controls that were previously published [15].
J. Blomberg (Uppsala University, Uppsala, Sweden)
assayed DNA by qPCR from trans-urethral resections
from prostate tissue of 400 patients with benign or
malignant prostatic hyperplasia from Umeå University
Hospital, all of which were negative. There were three
posters on prostate cancer. N. Makarova (Emory Uni-
versity, Atlanta, Georgia) described an XMRV neutraliz-
ing antibody (NAb) assay. Sera from 16 of 258 prostate
cancer patients screened (6.2%) were positive for XMRV
Nab, which is lower than in their original study [4]. Y.
Ikeda (Mayo Clinic, Rochester, Minnesota) showed a
number of XMRV-positive biopsy samples using nested
PCR for gag (1 of 40 normal/benign, 4 of 70 intermedi-
ate prostate cancers, and 1 of 40 high-grade prostate
cancers at the Mayo Clinic). However, no XMRV-speci-
fic 24 bp deletion was found in the gag leader regions of
the PCR-positive clinical samples. J. Das Gupta (Cleve-
land Clinic, Cleveland, Ohio) described a novel qPCR
assay for detecting XMRV RNA in urine. About 26% of
prostate cancer cases (31/120) were XMRV positive,
while 1/22 urine specimens (4.3%) from normal healthy
control individuals was XMRV positive. Urine samples
were negative for mouse mitochondrial DNA.
XMRV and Chronic Fatigue Syndrome
Pointing out that mouse cells contain ~50 copies each
of endogenous MLV DNA, and that less than one cell’s
worth could yield a detectable PCR product, B. Huber
(Tufts University, Boston, Massachusetts) emphasized
the urgent need to distinguish contaminating mouse
sequences from true XMRV infections. PBMC DNA was
tested for XMRV by qPCR and nested PCR, using pri-
mers specific for regions of the XMRV pol and gag
genes, respectively. In addition Dr. Huber’s group
assessed potential mouse DNA contamination using
both qPCR for murine mitochondrial cytochrome oxi-
dase and/or conventional PCR for IAP DNA. While
control experiments verified the sensitivity of all assays,
her group failed to detect XMRV in 184 CFS patients
and 25 healthy controls. However, positive results were
obtained with some samples using the gag nested PCR
assays. DNA sequencing of the PCR products revealed
sequences identical to those described from prostate
cancer and CFS patients, in addition to sequences more
closely related to endogenous MLVs. However all sam-
ples testing positive for XMRV or MLV DNA were also
positive for mouse IAP and mitochondrial DNA, using
either assay. The source of this apparent contamination
is under investigation.
Contrasting data was subsequently presented by M.
Hansen (Cornell University, Ithaca, New York), who
summarized a blinded study ("10/10/10” study) designed
to determine whether XMRV could be detected in
PBMCs from three small groups of subjects from a sin-
gle geographic area. Study subjects (10 per group) were
classified as severely ill with, or recovered from, CFS. A
control group lacked a CFS diagnosis at any time.
XMRV RNA was evaluated by nested RT-PCR, using
gag primers [1]. In addition, PCR with mouse mitochon-
drial DNA primers were used on all cDNA preparations
to exclude mouse cell contamination. Gag sequences
similar to polytropic MLV were detected in 8 of the
severely-ill CFS patients, 3 of those who had recovered,
and one of the controls. In order to determine whether
infectious virus could be recovered, a subset of these
blood samples was incubated with LNCaP cells followed
by serial passage over several weeks. PCR analysis
revealed that cultures exhibiting gag sequences corre-
sponded to those inoculated with CFS patient plasma.
Although a relatively small study, the prevalence of
virus in severe or recovered CFS patients (55%) relative
to the control group (10%) strengthened the findings of
Lombardi et al. [3].
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Supporting the results of the Cornell study, S.C. Lo,
(FDA/CBER, Bethesda, Maryland) reviewed his pre-
viously published findings on the presence of MLV-
related virus gene sequences in both CFS patients and
healthy controls [31]. A unique feature of this study was
that portions of the CFS blood samples had been main-
tained in frozen storage at -80°C from the mid 1990s.
Using nested PCR, MLV-like gag gene sequences could
be amplified from PBMC DNA in 32 of 37 patients
meeting the accepted diagnostic criteria for CFS (86.5%)
compared with only 3 of 44 (6.8%) healthy volunteer
blood donors. This study also detected viral RNA in the
frozen plasma samples of these CFS patients. However,
gag and env sequences from CFS patients were more
closely related to those of polytropic mouse endogenous
retroviruses than to XMRV. Recognizing the increasing
concerns of contamination (including the PCR primers
themselves, laboratory reagents or commonly used viral
vectors), semi-nested PCR was used to demonstrate the
absence of mouse mitochondrial DNA. Dr. Lo pointed
out in his concluding statements that additional studies
are needed to determine whether MLV-related viruses
have a causal or secondary role in the development of
either CFS and prostate cancer.
Two European studies failed to detect XMRV infec-
tion in CFS and MS patients. A study presented by
N. Bannert (Robert Koch-Institute, Berlin, Germany)
failed to detect the presence of antibodies against gag
and env in serum from 36 CFS patients (Fukada/CDC
criteria), 50 multiple sclerosis patients (fatigue severity
scale 4,7+/-1.07) and 17 healthy individuals. In addition
XMRV was not detected in DNA isolated from stimu-
lated PBMCs of 39 CFS, 50 MS and 30 healthy controls
using a nested PCR, and reverse transcriptase activity
was absent from the supernatant from stimulated
PBMCs. Co-cultivation of PBMCs from a subset of
patients with LNCaP indicator failed to recover infec-
tious virus.
J. Blomberg (Uppsala University, Uppsala, Sweden)
investigated 50 CFS patients (Fukada criteria) using
virus isolation with LNCaP cells with patient plasma as
inoculum from 40 of these patients. Cultures were mon-
itored at day 5 with integrase qPCR, potential positive
cultures were passed for another 5 days. Though three
cultures were initially positive with a few copies, only
one could be passed twice, but not further. The other
two initially positive cultures lost signal after the first
passage. Virus was not recovered. Serological testing
was performed on 60 CFS samples and 100 blood
donors using a multi-epitope approach with 22 peptides
spanning Gag and Envelope coated on Luminex beads.
Peptides were designed to react broadly by conserved
sequence selection and inclusion of degenerate amino
acids. Sera with a reaction above background (non-
coated beads) against minimally three peptides were
considered positive. One blood donor sample and two
CFS samples reacted in this fashion. The authors con-
cluded that XMRV and related viruses are rare in
Sweden.
A poster of Blanco et al. (Irsi Caixa Foundation,
Barcelona, Spain) used an alternative approach to look
for XMRV. PBMCs from patients were immortalised by
infection with Epstein Barr virus, DNA extracted from
cell pellets and tested for XMRV using real time PCR
for pol (50-nt) and two nested PCR assays for gag and
env genes. Eleven CFS patients (Fukada and Canadian
criteria) and 5 healthy donors were tested. Three CFS
patients and one control were found positive in the
nested env approach, one CFS patient and one control
in the gag nested PCR, and four CFS patients and two
controls in the real time pol PCR assays. Sequencing of
the three gag amplicons found the 24-nt deletion char-
acteristic of XMRV. The authors concluded that EBV-
transformed cell lines can harbour XMRV specific
sequences.
The final presentation of the CFS session was deliv-
ered by J. Mikovits (Whittemore Peterson Institute,
Reno, NV) who shared data on a recent study detecting
XMRV in the peripheral blood of CFS patients in the
United Kingdom. All study patients (50) met the
requirements for CFS based on rigorous criteria. Periph-
eral blood from these patients was shipped to NCI-Fre-
derick for plasma and PBMC isolation, after which
serology and virus isolation were performed at two dif-
ferent laboratories. A multi-faceted approach involved
(i), nested RT-PCR for gag or env sequences (ii) detec-
tion of Env antibodies in plasma (iii), Western analysis
from LNCaP cells co-cultured with subject’s cell-free
plasma and (iv), immunological detection of viral pro-
teins expressed by activated PBMCs. Collectively, this
study indicated the presence of infectious virus in >60%
of CFS patients. XMRV could be transmitted either cell-
associated or cell-free from both activated lymphocytes
and plasma from infected individuals by passage to
LNCaP. Maintaining that the worldwide distribution of
XMRV is greater than previously assumed, Dr. Mikovits
concluded her presentation by calling for additional stu-
dies addressing the replication and pathogenesis of
XMRV in the human population, as well as prioritizing
the development of antiviral agents for testing in the
appropriate clinical setting.
Development of XMRV Diagnostic Tools
A central theme of the Workshop was the availability to
the research community of reliable diagnostic reagents
for nucleic acid testing, serology and virus culture. Addi-
tionally, there was general consensus among attendees
for including sensitive PCR methods to detect
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contaminating MLV-related and mouse DNA. Based on
the ability to recapitulate a non-human primate model
of XMRV infection [21], X. Qiu (Abbott Diagnostics,
Illinois) presented an update on their collaboration with
researchers at Emory University and the Cleveland
Clinic to develop a series of high-throughput immu-
noassays for future epidemiological studies. Using serum
from XMRV-inoculated rhesus macaques and a viral
lysate as source of antigen, antibody responses were
detected for surface subunit (SU) Envelope protein,
9 days post-inoculation, followed by the trans-mem-
brane protein p15E (TM) at Day 11 and Capsid (CA) at
Day 14. Chemiluminescence-based indirect (anti-
human) and direct (double antigen) assay formats based
on each of these antigens are currently under develop-
ment. By changing the source of SU from a bacterial to
a mammalian expression system and incorporating Avi-
din Biotin Complex signal amplification, sensitivity of
the SU immunoassay was improved >1000-fold. The
prototype, direct SU assay provided substantial discrimi-
nation between a blood donor negative population and
the 29 XMRV seropositive primate bleeds.
R. Bagni (SAIC-Frederick, Frederick, Maryland) sum-
marized current NCI efforts to develop serological
reagents for XMRV. In the absence of a bona fide, pedi-
greed antibody-positive clinical control, a “training set”
of 116 samples, 39 of which were designated XMRV-
positive from the Lombardi et al. study, were examined
for the presence of XMRV-specific antibodies. Of the 9
candidate XMRV proteins, a strong serological response
to the SU and TM, and CA was observed, while to a les-
ser extent, antibodies to p12, MA and NC could be
detected. Dr. Bagni also introduced the concept of a
“positivity algorithm”, i.e. the number of XMRV antigens
for which an immunological response must be detected
before designating a sample positive. A total of 64
expression clones constructed for development of the
NCI XMRV ELISA has now been deposited at the NIH
AIDS Research and Reference Reagent Program https://
www.aidsreagent.org to be accessed by researchers of
the extramural community.
As a valuable complement of nucleic acid and serolo-
gical assay reagents, K. Lee (NCI, Frederick, Maryland)
described the development of a novel cell line to rapidly
assess XMRV or XMLV replication. Detectors of Exo-
genous Retroviral Sequence Elements, or DERSE indica-
tor cells, exploit a specialized retroviral vector
containing an inverted, intron-interrupted green fluores-
cent protein (GFP) reporter cassette. Although GFP is
not expressed within a target cell after an initial infec-
tion, transfer of an intron-less vector to new cells during
a second round of XMRV infection permitted GFP
expression, which can be easily monitored by micro-
scopy. Importantly, the DERSE cell line permits virus
detection in a little as three days, representing a consid-
erable time saving over standard methods. Dr. Lee indi-
cated that this cell line will be deposited in the NIH
AIDS Reagent Repository for use by researchers in the
extramural community. While clearly not intended for
first-line (high throughput) analysis, the DERSE cell line
will most certainly find use as a confirmatory strategy.
M. Kearney (NCI, Frederick, Maryland) presented two
highly-sensitive single-copy assays for detection of both
XMRV and MLV-related viruses in blood products. The
first of these, the XMRV single copy assay, or X-SCA, is
a qualitative PCR assay (analogous to that employed for
HIV detection) capable of detecting a single pelletable
virion in plasma or XMRV DNA in whole blood or
PBMC. As a complement, the XMRV single genome
sequencing assay (X-SGS) likewise facilitates individual
sequencing of large genomic fragments. Preliminary data
indicated that X-SCA compared favorably in specificity
and sensitivity with related protocols under development
at the FDA, CDC, Whittemore-Peterson Institute and
Blood Systems Research Institute. In combination,
X-SCA and X-SGS are capable of discriminating
between XMRV and contaminating mouse endogenous
viruses with 100% accuracy.
The concluding presentation of G. Simmons (Blood
Systems Research Institute, San Francisco, California)
set the stage for discussing future actions to help resolve
disparate results presented during the Workshop. The
Blood XMRV Scientific Research Working Group
(Blood XMRV SRWG) was established as a National
Heart, Lung and Blood Institute (NHBLI) coordinated
working group to design and coordinate collaborative
studies to standardize existing assays and investigate the
prevalence of XMRV in blood donors. A four-phase,
multi-center study was described, wherein Phase 1
involved PCR testing, in a blinded fashion, of analytical
performance panels comprising pedigreed negative
blood and plasma spiked with serial dilutions of XMRV
infected cells and supernatants, respectively. In general,
there was good agreement between participating labora-
tories. Phase II will compare XMRV nucleic acid detec-
tion in frozen PBMCs, whole blood and plasma from
CFS patients previously identified as viremic. Impor-
tantly, replicate blood specimens would be processed at
different storage intervals to determine whether the 2-
4 day processing period common to many blood donor
repositories affects assay performance. Phases III and IV
will extend these studies to begin to examine the preva-
lence of XMRV in blood donors by both nucleic acid
and serological methods.
The Path Forward - Consensus and Caution
Considering the discrepancies between the different stu-
dies regarding the prevalence of XMRV, it became
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abundantly clear that reaching consensus on protocols
for PCR amplification, for discriminating between
XMRV and contaminating mouse endogenous viruses,
and sample storage and processing should be an
immediate priority among groups studying XMRV. The
studies of the Blood XMRV SRWG are likely to be of
great importance in developing such a consensus. The
availability of analytical performance panels comprising
pedigreed samples would also be an enormous benefit
to researchers. The scientific community might also
consider establishing a “repository” where protocols can
be publicly deposited and compared, which could reveal
nuances underlying the discrepancies observed when
similar reagents are used by different groups.
Finally, there was vigorous discussion about the use
and timing of interventions targeted against XMRV in
CFS and prostate cancer patients. Although a small
number of workshop participants advocated the
immediate use of antiretrovirals that have successfully
controlled HIV infection, and while a well-controlled,
randomized clinical trial should not be ruled out, pro-
ceeding with caution was emphasized. Until (a) a causal
role for XMRV in CFS or prostate cancer is firmly
established (b), objective biomarkers are defined, and (c)
uniformly-accepted assays to monitor effects on virus
replication are in place, the off-label use of antiretrovir-
als and anecdotal reports of their efficacy will be unac-
ceptable to third party payers/regulators, and could
potentially keep valuable therapies out of reach of many
patients.
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